Intra-Cellular Therapies, Inc.
- Jurisdiction
United States - LEI
5299002U2KGF193IJA20 - ISIN
US46116X1019 (ITCI )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Read full profile
Stock price
Fundamentals
- Net revenue
€583.99M - Gross margin
91.6% - EBIT
-€100.15M - EBIT margin
-17.1% - Net income
-€64.07M - Net margin
-11.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts
Products
| Product | Revenue | |
|---|---|---|
| Product |
| |
| Grant |
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Josh Gottheimer | May 14, 2025 | $1.00K–$15.00K |
| Gilbert Cisneros | May 6, 2025 | $1.00K–$15.00K |
| Josh Gottheimer | April 10, 2025 | $1.00K–$15.00K |
| Gilbert Cisneros | April 7, 2025 | $1.00K–$15.00K |
| Josh Gottheimer | February 10, 2025 | $1.00K–$15.00K |
Earnings Calls
Latest earnings call: May 7, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
| George Soros |
|
|
|
Buy |